Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.64 |
| ▸ | CHRNB3 | Q05901 | 9/20 | 0.64 |
| ▸ | CHRNA6 | Q15825 | 9/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435652 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12820268 | 0.83 | CHRNB2 (0.67) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1383584 | 0.83 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1383582 | 0.83 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL7498965 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16472339 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15998838 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13949187 | 0.79 | — | — | |
| SCHEMBL1978271 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16509278 | 0.78 | BIRC2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| CN-106536524-A | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | 阿斯利康(瑞典)有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9271971-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| WO-2011038161-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038163-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CHRNB2 40/4885CHRNA3 32/4885CHRNA4 23/4885 |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | CHRNB2 40/4885CHRNA3 34/4885CHRNA4 24/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | CHRNB2 50/4885CHRNA3 54/4885CHRNA4 46/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CHRNB2 40/4885CHRNA3 33/4885CHRNA4 23/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | CHRNB2 40/4885CHRNA3 35/4885CHRNA4 23/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | CHRNB2 4718/4885CHRNA3 3892/4885CHRNA4 4325/4885 |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CHRNB2 40/4885CHRNA3 33/4885CHRNA4 23/4885 |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | AVPR2, AVPR1A, VHL | CHRNB2 4718/4885CHRNA3 3892/4885CHRNA4 4325/4885 |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CHRNB2 40/4885CHRNA3 33/4885CHRNA4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.